Apoptotic pathways as a therapeutic target for colorectal cancer treatment

World Journal of Gastrointestinal Oncology

Volumn 8, Issue 8, 2016, Pages 583-591

  Abraha, Aman M ^a   Ketema, Ezra B ^a  

^a MEKELLE UNIVERSITY   (Ethiopia)

Author keywords

Apoptosis; Apoptotic pathways; Colorectal cancer; Colorectal cancer therapies; Drug resistance

Indexed keywords

CASPASE INHIBITOR; CELL NUCLEUS DNA; DEOXYRIBONUCLEASE; PROTEIN BCL 2; PROTEIN P53; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 6;

APOPTOSIS; ARTICLE; CANCER THERAPY; CARCINOGENESIS; CELL FUNCTION; COLON POLYPOSIS; COLORECTAL CANCER; DOWN REGULATION; GENE EXPRESSION; HUMAN; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN TARGETING; RNA INTERFERENCE;

EID: 85010014153     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/WJGO.V8.I8.583     Document Type: Article

References (90)

1. 1 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96 [PMID: 18287387 DOI: 10.3322/CA.2007.0010]
2. 2 Vogelstein B, Kinzler KW. The genetic basis of human cancer. 2nd ed. New York: McGraw-Hill, 2002: 583-612
3. 3 Kheirelseid EAH, Miller N, Kerin MJ. Molecular biology of colorectal cancer: Review of the literature. Am J Molecul Biol 2013; 3: 72-80 [DOI: 10.4236/ajmb.2013.32010]
4. 4 Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55: 178-194 [PMID: 15890640 DOI: 10.3322/canjclin.55.3.178]
5. 5 Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Evans TR, Sansom OJ. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 2010; 107: 246-251 [PMID: 20018721 DOI: 10.1073/pnas.0908428107]
6. 6 Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, Bao JK. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif 2012; 45: 487-498 [PMID: 23030059 DOI: 10.1111/j.1365-2184.2012.00845]
7. 7 Kumar V, Abbas AK, Fausto N, Aster JC. Robins and Cotran: pathologic basis of disease. 8th ed. Philadelphia: Saunders Elsevier, 2010: 25-32
8. 8 Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005; 115: 2665-2672 [PMID: 16200200 DOI: 10.1172/JCI26252]
9. 9 O’Brien MA, Kirby R. Apoptosis. a review of pro-apoptotic and antiapoptotic pathways and dysregulation in disease. J Vet Emerg Crit Care 2008; 18: 572-585 [DOI: 10.1111/j.1476-4431.2008.0036]
10. 10 Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-4811 [PMID: 16892092 DOI: 10.1038/sj.onc.1209608]
11. 11 Schneider P, Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv 2000; 74: 281-286 [PMID: 10812970 DOI: 10.1016/S0031-6865(99)00038-2]
12. 12 Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002; 296: 1635-1636 [PMID: 12040174 DOI: 10.1126/ science.1071553]
13. 13 Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-219 [PMID: 14744432 DOI: 10.1016/S0092-8674(04)00046-7]
14. 14 Ziegler U, Groscurth P. Morphological features of cell death. News Physiol Sci 2004; 19: 124-128 [PMID: 15143207 DOI: 10.1152/ nips.01519.2004]
15. 15 Szegezdi E, Fitzgerald U, Samali A. Caspase-12 and ER-stress-mediated apoptosis: the story so far. Ann N Y Acad Sci 2003; 1010: 186-194 [PMID: 15033718 DOI: 10.1196/annals.1299.032]
16. 16 Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 2011; 30: 87 [PMID: 21943236]
17. 17 Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163 [PMID: 17237344 DOI: 10.1152/physrev.00013.2006]
18. 18 Hengartner MO. Apoptosis: corralling the corpses. Cell 2001; 104: 325-328 [PMID: 11239389 DOI: 10.1016/S0092-8674(01)00219-7]
19. 19 Fulda S, Gorman AM, Hori O, Samali A. Cellular Stress Responses: Cell Survival and Cell Death. Hindawi Publishing Corporation; Int J Cell Biol 2010; 2010: 214074 [PMID: 20182529 DOI: 10.1155/2010/214074]
20. 20 Goldar S, Khaniani MS, Derakhshan SM, Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev 2015; 16: 2129-2144 [PMID: 25824729 DOI: 10.7314/APJCP.2015.16.6.2129]
21. 21 Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 2003; 63: 1608-1614 [PMID: 12670912]
22. 22 Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011; 8: 686-700 [PMID: 22009203 DOI: 10.1038/nrgastro.2011.173]
23. 23 Tang R, Changchien CR, Wu MC, Fan CW, Liu KW, Chen JS, Chien HT, Hsieh LL. Colorectal cancer without high microsatellite instability and chromosomal instability–an alternative genetic pathway to human colorectal cancer. Carcinogenesis 2004; 25: 841-846 [PMID: 14729584 DOI: 10.1093/carcin/bgh074]
24. 24 Watson AJ. Apoptosis and colorectal cancer. Gut 2004; 53: 1701-1709 [PMID: 15479695]
25. 25 Fearon ER, Vogelstein B. A genetic model for colorectal tumo-rigenesis. Cell 1990; 61: 759-767 [PMID: 2188735 DOI: 10.1016/0092 -8674(90)90186-I]
26. 26 Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66: 589-600 [PMID: 1651174 DOI: 10.1016/0092-8674(81)90 021-0]
27. 27 Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359: 235-237 [PMID: 1528264]
28. 28 Miyashiro I, Senda T, Matsumine A, Baeg GH, Kuroda T, Shimano T, Miura S, Noda T, Kobayashi S, Monden M. Subcellular localization of the APC protein: immunoelectron microscopic study of the association of the APC protein with catenin. Oncogene 1995; 11: 89-96 [PMID: 7624136]
29. 29 Smith KJ, Johnson KA, Bryan TM, Hill DE, Markowitz S, Willson JK, Paraskeva C, Petersen GM, Hamilton SR, Vogelstein B. The APC gene product in normal and tumor cells. Proc Natl Acad Sci USA 1993; 90: 2846-2850 [PMID: 8385345 DOI: 10.1073/ pnas.90.7.2846]
30. 30 Kulendran M, Stebbing JF, Marks CG, Rockall TA. Predictive and prognostic factors in colorectal cancer: a personalized approach. Cancers (Basel) 2011; 3: 1622-1638 [PMID: 24212777 DOI: 10.3390/cancers3021622]
31. 31 Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-2460 [PMID: 20018966 DOI: 10.1056/NEJMra0804588]
32. 32 Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-1851 [PMID: 10921899]
33. 33 Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, Ochiai A, Hirohashi S. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 2000; 60: 4761-4766 [PMID: 10987283]
34. 34 Watson SA. Oncogenic targets of beta-catenin-mediated transcription in molecular pathogenesis of intestinal polyposis. Lancet 2001; 357: 572-573 [PMID: 11558478 DOI: 10.1016/S0140-6736(00)04074-5]
35. 35 Buchanan FG, DuBois RN. Connecting COX-2 and Wnt in cancer. Cancer Cell 2006; 9: 6-8 [PMID: 16413466 DOI: 10.1016/ j.ccr.2005.12.029]
36. 36 Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003; 22: 9030-9040 [PMID: 14663481 DOI: 10.1038/sj.onc.1207116]
37. 37 Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio N, Givol D. DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. Oncogene 2001; 20: 3449-3455 [PMID: 11423996 DOI: 10.1038/sj.onc.1204446]
38. 38 Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 2002; 4: 842-849 [PMID: 12402042 DOI: 10.1038/ ncb866]
39. 39 Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW. Regulation of PTEN transcription by p53. Mol Cell 2001; 8: 317-325 [PMID: 11545734 DOI: 10.1016/S1097-2765(01)00323-9]
40. 40 Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104: 263-269 [PMID: 10430607 DOI: 10.1172/ JCI6863]
41. 41 Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat 2003; 21: 271-276 [PMID: 12619112 DOI: 10.1002/humu.10175]
42. 42 Plentz RR, Wiemann SU, Flemming P, Meier PN, Kubicka S, Kreipe H, Manns MP, Rudolph KL. Telomere shortening of epithelial cells characterises the adenoma-carcinoma transition of human colorectal cancer. Gut 2003; 52: 1304-1307 [PMID: 12912862 DOI: 10.1136/gut.52.9.1304]
43. 43 Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911 [PMID: 10444588 DOI: 10.1101/gad.13.15.1899]
44. 44 Merritt AJ, Potten CS, Watson AJ, Loh DY, Nakayama K, Nakayama K, Hickman JA. Differential expression of bcl-2 in intestinal epithelia. Correlation with attenuation of apoptosis in colonic crypts and the incidence of colonic neoplasia. J Cell Sci 1995; 108 (Pt 6): 2261-2271 [PMID: 7673346]
45. 45 Bosari S, Moneghini L, Graziani D, Lee AK, Murray JJ, Coggi G, Viale G. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol 1995; 26: 534-540 [PMID: 7750937 DOI: 10.1016/0046-8177(95)90250-3]
46. 46 Bronner MP, Culin C, Reed JC, Furth EE. The bcl-2 protooncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 1995; 146: 20-26 [PMID: 7856728]
47. 47 Flohil CC, Janssen PA, Bosman FT. Expression of Bcl-2 protein in hyperplastic polyps, adenomas, and carcinomas of the colon. J Pathol 1996; 178: 393-397 [PMID: 8691316 DOI: 10.1002/(SICI)1 096-9896(199604)178]
48. 48 Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997; 34: 9-19 [PMID: 9408956]
49. 49 Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 1996; 56: 2422-2427 [PMID: 8625322]
50. 50 Bindal AK, Storrs BB, McLone DG. Management of the DandyWalker syndrome. Pediatr Neurosurg 1990; 16: 163-169 [PMID: 2134009 DOI: 10.1039/c0ib00144a]
51. 51 Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-2026 [PMID: 8156506 DOI: 10.1002/1097-0142(19940415)73]
52. 52 Hao X, Du M, Bishop AE, Talbot IC. Imbalance between proliferation and apoptosis in the development of colorectal carcinoma. Virchows Arch 1998; 433: 523-527 [PMID: 9870685 DOI: 10.1007/s004280050284]
53. 53 Hawkins N, Lees J, Hargrave R, O’Connor T, Meagher A, Ward R. Pathological and genetic correlates of apoptosis in the progression of colorectal neoplasia. Tumour Biol 1997; 18: 146-156 [PMID: 9143411 DOI: 10.1159/000218025]
54. 54 Fulda S. Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol 2010; 2010: 370835 [PMID: 20182539 DOI: 10.1155/2010/370835]
55. 55 Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008; 118: 1979-1990 [PMID: 18523647]
56. 56 Hassen S, Ali N, Chowdhury P. Molecular signaling mechanisms of apoptosis in hereditary non-polyposis colorectal cancer. World J Gastrointest Pathophysiol 2012; 3: 71-79 [PMID: 22737591 DOI: 10.4291/wjgp.v3.i3.71]
57. 57 Reed JC. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol 2006; 3: 388-398 [PMID: 16826219]
58. 58 Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ 2005; 12 Suppl 1: 942-961 [PMID: 15665817 DOI: 10.1038/sj.cdd.4401556]
59. 59 O’Connell J, O’Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082 [PMID: 9064324 DOI: 10.1084/jem.184.3.1075]
60. 60 Petak I, Douglas L, Tillman DM, Vernes R, Houghton JA. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin Cancer Res 2000; 6: 4119-4127 [PMID: 11051265]
61. 61 Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008; 19: 325-331 [PMID: 18495520 DOI: 10.1016/j.cytogfr.2008.04.001]
62. 62 Sträter J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, Herfarth C, Möller P, Lehnert T. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 2002; 8: 3734-3740 [PMID: 12473583]
63. 63 Sayers TJ, Murphy WJ. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 2006; 55: 76-84 [PMID: 15864587 DOI: 10.1007/s00262-005-0676-3]
64. 64 Rigillo N, Meloni T, Torelli M, Schettini F. [Haptoglobin and orosomucoid in the blood in a case of congenital afibrinogenemia and in the family of the patient]. Boll Soc Ital Biol Sper 1968; 44: 81-83 [PMID: 5651986 DOI: 10.1186/1471-2407-5-5]
65. 65 Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 2004; 64: 4900-4905 [PMID: 15256461 DOI: 10.1158/0008-5472.CAN-04-0408]
66. 66 Mishier JM, Jackson CA, Nicora RW, Julien RM. Comparison of two lidocaine preparations by in vivo assay methods. Am J Hosp Pharm 1975; 32: 489-491 [PMID: 1146818 DOI: 10.1182/blood. V98.3.795]
67. 67 Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, Mayer EG, Yu H, Pardoll DM, Ashkenazi A, Bedi A. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res 2004; 64: 9105-9114 [PMID: 15604280 DOI: 10.1158/0008-5472. CAN-04-2488]
68. 68 Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277-288 [PMID: 12001989 DOI: 10.1038/nrc776]
69. 69 Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest 2005; 115: 2648-2655 [PMID: 16200198 DOI: 10.1172/JCI26250]
70. 70 Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126-1132 [PMID: 19228717 DOI: 10.1158/1078-0432.CCR-08-0144]
71. 71 Galluzzi L, Morselli E, Kepp O, Vitale I, Rigoni A, Vacchelli E, Michaud M, Zischka H, Castedo M, Kroemer G. Mitochondrial gateways to cancer. Mol Aspects Med 2010; 31: 1-20 [PMID: 19698742]
72. 72 Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-2087.e3 [PMID: 20420947]
73. 73 Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, Harousseau JL, Amiot M, Bataille R. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005; 19: 1248-1252 [PMID: 15902294 DOI: 10.1038/sj.leu.2403784]
74. 74 Singh R, Saini N. Downregulation of BCL2 by miRNAs augments drug-induced apoptosis–a combined computational and experimental approach. J Cell Sci 2012; 125: 1568-1578 [PMID: 22328513 DOI: 10.1242/jcs.095976]
75. 75 Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403 [PMID: 15694340 DOI: 10.1016/j.molcel.2004.12.030]
76. 76 Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228: 1440-1443 [PMID: 3874430 DOI: 10.1126/science.3874430]
77. 77 Leahey MD, Logan SA, McArthur RG. Pediatric diabetes: a new teaching approach. Can Nurse 1975; 71: 18-20 [PMID: 1175148]
78. 78 Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets 2014; 15: 80-89 [PMID: 24387333 DOI: 10.2174/1389450114666140106101412]
79. 79 Tymochkiv PM. [Frequency of abnormal tolerance to glucose in people with predisposition to diabetes]. Vrach Delo 1977; (1): 70-73 [PMID: 847952 DOI: 10.1038/362857a0]
80. 80 Iancu-Rubin C, Mosoyan G, Glenn K, Gordon RE, Nichols GL, Hoffman R. Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis. Exp Hematol 2014; 42: 137-145.e5 [PMID: 24309210 DOI: 10.1016/j.exphem.2013.11.012]
81. 81 Sosin AM, Burger AM, Siddiqi A, Abrams J, Mohammad RM, Al-Katib AM. HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas. J Hematol Oncol 2012; 5: 57 [PMID: 22989009 DOI: 10.1186/1756-8722-5-57]
82. 82 Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, Sapino A, Zhang F, Sharma D, Yang XH, Tora AD, Mehta K. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 2002; 21: 8843-8851 [PMID: 12483536 DOI: 10.1038/sj.onc.1206044]
83. 83 LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER, Yu D, Wang H, Wang W, Zhang R, Agrawal S, Gillard JW, Durkin JP. Preclinical characterization of AEG35156/ GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 2006; 12: 5231-5241 [PMID: 16951243]
84. 84 Ivan Teodosovich Shevchenko (on his 70th birthday). Vopr Onkol 1975; 21: 131-132 [PMID: 1108433 DOI: 10.1016/S0960-9822(00)00781-8]
85. 85 Philchenkov A, Zavelevich M, Kroczak TJ, Los M. Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp Oncol 2004; 26: 82-97 [PMID: 15273659]
86. 86 Rohn JL, Noteborn MH. The viral death effector Apoptin reveals tumor-specific processes. Apoptosis 2004; 9: 315-322 [PMID: 15258463 DOI: 10.1023/B: APPT.0000025808.48885.9c]
87. 87 Guo F, Nimmanapalli R, Paranawithana S, Wittman S, Griffin D, Bali P, O’Bryan E, Fumero C, Wang HG, Bhalla K. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 2002; 99: 3419-3426 [PMID: 11964312 DOI: 10.1182/blood.V99.9.3419]
88. 88 Burz C, Berindan-Neagoe I, Balacescu O, Irimie A. Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol 2009; 48: 811-821 [PMID: 19513886 DOI: 10.1080/0284186 0902974175]
89. 89 Kubba AK. Non-steroidal anti-inflammatory drugs and colorectal cancer: is there a way forward? Eur J Cancer 1999; 35: 892-901 [PMID: 10533468 DOI: 10.1016/S0959-8049(99)00054-4]
90. 90 Sharma RA, Manson MM, Gescher A, Steward WP. Colorectal cancer chemoprevention: biochemical targets and clinical development of promising agents. Eur J Cancer 2001; 37: 12-22 [PMID: 11165125 DOI: 10.1016/S0959-8049(00)00326-9]